Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.06.2018 | Case report

Adalimumab/infliximab

Anaphylactic reaction: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Maina N, et al. Heterozygous pathogenic TNFRSF13B (TACI) variant in a patient with pediatric onset, difficult-to-treat inflammatory bowel disease. Journal of Clinical Immunology 38: 367-368 abstr. 79, No. 3, Apr 2018. Available from: URL: http://doi.org/10.1007/s10875-018-0485-z [abstract] - USA Maina N, et al. Heterozygous pathogenic TNFRSF13B (TACI) variant in a patient with pediatric onset, difficult-to-treat inflammatory bowel disease. Journal of Clinical Immunology 38: 367-368 abstr. 79, No. 3, Apr 2018. Available from: URL: http://​doi.​org/​10.​1007/​s10875-018-0485-z [abstract] - USA
Metadaten
Titel
Adalimumab/infliximab
Anaphylactic reaction: case report
Publikationsdatum
01.06.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-48118-2

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Warfarin

Case report

Ascorbic acid

Case report

Antineoplastics

Case report

Phenytoin